Marty Makary/hub.jhu.edu
Jun 13, 2025, 10:38
Marty Makary Outlines His Priorities for a New FDA, One That Cuts Unnecessary Delays and Puts Patients First
U.S. FDA shared a post on X:
“In a new FDA Direct conversation, Marty Makary outlines his priorities for a new FDA, one that cuts unnecessary delays and puts patients first.
In the latest FDA Direct conversation, Commissioner Marty Makary and Dr. Vinay Prasad discussed their highest priorities for a new FDA, as outlined in a recent JAMA article.
Here’s a quick overview of the topics discussed:
Marty Makary wants to see more cures and meaningful treatments for the American public. To speed effective products to market, FDA is focused on cutting unnecessary steps and red tape while preserving gold-standard science.
Animal studies often aren’t great predictive models. FDA is eager reduce unnecessary animal studies and pioneer better ways to assess toxicity and other metrics.
FDA is taking a critical look at our food supply, using the best science and common sense.
Big data, cloud storage and electronic health records are opening huge opportunities for innovative trial designs and better post-approval monitoring.
Clunky self-reported adverse event databases have numerous shortcomings. FDA is working on better solutions.
Marty Makary is willing to take risks and pursue big ideas to move the agency forward.”
Proceed to the video attached to the post.
More posts featuring U.S. FDA.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 13, 2025, 10:11
Jun 13, 2025, 09:43
Jun 13, 2025, 09:06
Jun 13, 2025, 08:53